Top

Published in:

01-06-2018 | Original Article

Serum C3/C4 ratio is a novel predictor of renal prognosis in patients with IgA nephropathy: a retrospective study

Authors: Min Pan, QiongXiu Zhou, ShuBei Zheng, XiaoHan You, Duo Li, Ji Zhang, ChaoSheng Chen, FeiFei Xu, ZhanYuan Li, ZhiHong Zhou, JianNa Zhang

Published in: Immunologic Research | Issue 3/2018

Abstract

IgA nephropathy (IgAN) is an autoimmune disease associated with complement activation. It is unclear whether the ratio of serum C3 and C4 concentrations (C3/C4 ratio) can predict renal outcomes in IgAN patients. A total of 1503 patients diagnosed with IgAN via renal biopsy were recorded in this study. Poor renal outcomes were defined as > 50% decrease in the baseline estimated glomerular filtration rate (eGFR) or development of end-stage renal disease (ESRD) during follow-up. In total, 712 patients meeting the exclusion/inclusion criteria were selected, and the mean follow-up period was 40.6 (12.34) months. Patients with decreased C3/C4 ratios displayed significantly more severe clinical characteristics and renal pathological features and a higher proportion of poor renal outcomes and ESRD. The optimal multivariate Cox regression models identified the C3/C4 ratio (hazard ratio (HR) 0.63, 95% CI 0.5–0.9), serum uric acid (HR 1.58, 95% CI 1.2–2.2), serum creatinine (HR 1.3, 95% CI 1.1–1.6), systolic blood pressure (HR 1.57, 95% CI 1.2–2.0) and T score (relative to T0, T1: HR 1.96, 95% CI 1.1–3.7, T2: HR 3.03, 95% CI 1.6–5.9) as strong predictors of poor renal outcomes. Subgroup analysis showed that patients with low C3/C4 ratios benefited from glucocorticoids or other immunosuppressive agents (hazard ratio 0.30 and 0.18, 95% CI 0.13–0.72 and 0.07–0.46, respectively). Serum C3/C4 ratios may be an independent novel predictor of renal outcomes in IgAN patients. Decreased C3/C4 ratios suggest poor renal outcomes and the potential to benefit from aggressive immunosuppressive therapies.

Lai KN, Tang SC, Schena FP, Novak J, Tomino Y, Fogo AB, et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2:16001. https://doi.org/10.1038/nrdp.2016.1.CrossRefPubMed

Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002;347(10):738–48. https://doi.org/10.1056/NEJMra020109.CrossRefPubMed

Sinniah R, Javier AR, Ku G. The pathology of mesangial IgA nephritis with clinical correlation. Histopathology. 1981;5(5):469–90.CrossRefPubMed

Donadio JV Jr, Grande JP. Immunoglobulin A nephropathy: a clinical perspective. J Am Soc Nephrol. 1997;8(8):1324–32.PubMed

Koscielska-Kasprzak K, Bartoszek D, Myszka M, Zabinska M, Klinger M. The complement cascade and renal disease. Arch Immunol Ther Exp. 2014;62(1):47–57. https://doi.org/10.1007/s00005-013-0254-x.CrossRef

Sacks S, Zhou W. New boundaries for complement in renal disease. J Am Soc Nephrol. 2008;19(10):1865–9. https://doi.org/10.1681/ASN.2007101121.CrossRefPubMed

Mao S, Zhang J. Role of complement in glomerular diseases. J Recept Signal Transduct Res. 2016;36(3):319–25. https://doi.org/10.3109/10799893.2015.1086882.CrossRefPubMed

Levy M, Berger J. Worldwide perspective of IgA nephropathy. Am J Kidney Dis. 1988;12(5):340–7.CrossRefPubMed

Floege J. The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches? Am J Kidney Dis. 2011;58(6):992–1004. https://doi.org/10.1053/j.ajkd.2011.05.033.CrossRefPubMed

10.

Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun. 2010;34(3):J276–86. https://doi.org/10.1016/j.jaut.2009.11.014.CrossRefPubMed

11.

Lhotta K, Schlogl A, Kronenberg F, Joannidis M, Konig P. Glomerular deposition of the complement C4 isotypes C4A and C4B in glomeruonephritis. Nephrol Dial Transplant. 1996;11(6):1024–8.CrossRefPubMed

12.

Zwirner J, Burg M, Schulze M, Brunkhorst R, Gotze O, Koch KM, et al. Activated complement C3: a potentially novel predictor of progressive IgA nephropathy. Kidney Int. 1997;51(4):1257–64.CrossRefPubMed

13.

Endo M, Ohi H, Ohsawa I, Fujita T, Matsushita M, Fujita T. Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant. 1998;13(8):1984–90.CrossRefPubMed

14.

Maillard N, Wyatt RJ, Julian BA, Kiryluk K, Gharavi A, Fremeaux-Bacchi V, et al. Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol. 2015;26(7):1503–12. https://doi.org/10.1681/ASN.2014101000.CrossRefPubMedPubMedCentral

15.

Ohsawa I, Ishii M, Ohi H, Tomino Y. Pathological scenario with the mannose-binding lectin in patients with IgA nephropathy. J Biomed Biotechnol. 2012;2012:476739. https://doi.org/10.1155/2012/476739.CrossRefPubMedPubMedCentral

16.

Yang X, Wei RB, Wang Y, Su TY, Li QP, Yang T, et al. Decreased serum C3 levels in immunoglobulin a (IgA) nephropathy with chronic kidney disease: a propensity score matching study. Med Sci Monit. 2017;23:673–81.CrossRefPubMedPubMedCentral

17.

Kim SJ, Koo HM, Lim BJ, Oh HJ, Yoo DE, Shin DH, et al. Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLoS One. 2012;7(7):e40495. https://doi.org/10.1371/journal.pone.0040495.CrossRefPubMedPubMedCentral

18.

Pan M, Zhang J, Li Z, Jin L, Zheng Y, Zhou Z, et al. Increased C4 and decreased C3 levels are associated with a poor prognosis in patients with immunoglobulin A nephropathy: a retrospective study. BMC Nephrol. 2017;18(1):231. https://doi.org/10.1186/s12882-017-0658-7.CrossRefPubMedPubMedCentral

19.

Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017;91(5):1014–21. https://doi.org/10.1016/j.kint.2017.02.003.CrossRefPubMed

20.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRefPubMedPubMedCentral

21.

Levey AS, Coresh J, Bolton K, Culleton B, Harvey KS, Ikizler TA et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 SUPPL. 1).

22.

Harrell Jr FE. rms: Regression Modeling Strategies. 2017.

23.

Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247(18):2543–6.CrossRefPubMed

24.

Harrell Jr FE, Dupont wcfC, others. m. Hmisc: Harrell miscellaneous. 2017.

25.

Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1–48.CrossRef

26.

Team RC. R: a language and environment for statistical computing. R Foundation for Statistical Computing: Vienna; 2017.

27.

KDIGO G. Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Inter, Suppl. 2012;2:139–274.CrossRef

28.

Magistroni R, D’Agati VD, Appel GB, Kiryluk K. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int. 2015;88(5):974–89. https://doi.org/10.1038/ki.2015.252.CrossRefPubMedPubMedCentral

29.

Couser WG. Pathogenesis and treatment of glomerulonephritis—an update. J Bras Nefrol. 2016;38(1):107–22. https://doi.org/10.5935/0101-2800.20160016. CrossRefPubMed

30.

Nielsen C, Fischer E, Leslie R. The role of complement in the acquired immune response. Immunology. 2000;100(1):4–12.CrossRefPubMedPubMedCentral

31.

Ibels LS, Gyory AZ. IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine (Baltimore). 1994;73(2):79–102.CrossRef

32.

Zhu B, Zhu CF, Lin Y, Perkovic V, Li XF, Yang R, et al. Clinical characteristics of IgA nephropathy associated with low complement 4 levels. Ren Fail. 2015;37(3):424–32. https://doi.org/10.3109/0886022X.2014.994408.CrossRefPubMed

33.

Yang Y, Chung EK, Zhou B, Blanchong CA, Yu CY, Fust G, et al. Diversity in intrinsic strengths of the human complement system: serum C4 protein concentrations correlate with C4 gene size and polygenic variations, hemolytic activities, and body mass index. J Immunol. 2003;171(5):2734–45.CrossRefPubMed

34.

Onda K, Ohi H, Tamano M, Ohsawa I, Wakabayashi M, Horikoshi S, et al. Hypercomplementemia in adult patients with IgA nephropathy. J Clin Lab Anal. 2007;21(2):77–84. https://doi.org/10.1002/jcla.20154.CrossRefPubMed

35.

Cheng GY, Liu DW, Zhang N, Tang L, Zhao ZZ, Liu ZS. Clinical and prognostic implications of serum uric acid levels on IgA nephropathy: a cohort study of 348 cases with a mean 5-year follow-up. Clin Nephrol. 2013;80(1):40–6. https://doi.org/10.5414/CN107813.CrossRefPubMed

36.

Zhou J, Chen Y, Liu Y, Shi S, Li X, Wang S, et al. Plasma uric acid level indicates tubular interstitial leisions at early stage of IgA nephropathy. BMC Nephrol. 2014;15:11. https://doi.org/10.1186/1471-2369-15-11.CrossRefPubMedPubMedCentral

37.

Tanaka T, Milaneschi Y, Zhang Y, Becker KG, Zukley L, Ferrucci L. A double blind placebo controlled randomized trial of the effect of acute uric acid changes on inflammatory markers in humans: a pilot study. PLoS One. 2017;12(8):e0181100. https://doi.org/10.1371/journal.pone.0181100.CrossRefPubMedPubMedCentral

38.

Wu J, Qiu L, Cheng XQ, Xu T, Wu W, Zeng XJ, et al. Hyperuricemia and clustering of cardiovascular risk factors in the Chinese adult population. Sci Rep. 2017;7(1):5456. https://doi.org/10.1038/s41598-017-05751-w.CrossRefPubMedPubMedCentral

39.

Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017;318(5):432–42. https://doi.org/10.1001/jama.2017.9362.CrossRefPubMedPubMedCentral

40.

Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225–36. https://doi.org/10.1056/NEJMoa1415463.CrossRefPubMed

41.

Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, et al. Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study. J Am Soc Nephrol. 2015;26(9):2248–58. https://doi.org/10.1681/ASN.2014070697.CrossRefPubMedPubMedCentral

42.

Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15(1):157–63.CrossRefPubMed

43.

Kamei K, Nakanishi K, Ito S, Saito M, Sako M, Ishikura K, et al. Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1301–7. https://doi.org/10.2215/CJN.08630910.CrossRefPubMedPubMedCentral

44.

Cuzick J. Forest plots and the interpretation of subgroups. Lancet. 2005;365(9467):1308.CrossRefPubMed

45.

Snaedal S, Heimburger O, Qureshi AR, Danielsson A, Wikstrom B, Fellstrom B, et al. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. Am J Kidney Dis. 2009;53(6):1024–33. https://doi.org/10.1053/j.ajkd.2009.02.008.CrossRefPubMed

Title: Serum C3/C4 ratio is a novel predictor of renal prognosis in patients with IgA nephropathy: a retrospective study
Authors: Min Pan
QiongXiu Zhou
ShuBei Zheng
XiaoHan You
Duo Li
Ji Zhang
ChaoSheng Chen
FeiFei Xu
ZhanYuan Li
ZhiHong Zhou
JianNa Zhang
Publication date: 01-06-2018
Publisher: Springer US
Published in: Immunologic Research / Issue 3/2018
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-018-8995-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Serum C3/C4 ratio is a novel predictor of renal prognosis in patients with IgA nephropathy: a retrospective study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2018

The class D scavenger receptor CD68 contributes to mouse chronic liver injury

Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study

A new theory on autoimmunity with reference to multiple sclerosis

Impact of mast cells in depression disorder: inhibitory effect of IL-37 (new frontiers)

Analytical variability in the determination of anti-double-stranded DNA antibodies: the strong need of a better definition of the old and new tests

Role of T cell-derived exosomes in immunoregulation